View Older Stories View More Recent Stories

May 12, 2022 11:02AM Stifel Reiterates Hold Rating, $3 Price Target on WAVE Life Sciences (WVE)
May 12, 2022 09:44AM Cantor Fitzgerald Reiterates Overweight Rating, $18 Price Target on Aravive (ARAV), "Peak Sales Potential of AVB-500 Remains Underappreciated"
May 12, 2022 06:24AM Mizuho Securities Reiterates Revance Therapeutic (RVNC) at Buy, "Encouraged by the Traction Gaining", "Assume Daxi Will Get Approved and Set Stage for Significant Upside"
May 12, 2022 06:21AM Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
May 12, 2022 06:15AM Oppenheimer Reiterates Outperform Rating, $25 Price Target on PDS Biotechnology Corp (PDSB)
May 12, 2022 06:13AM Needham & Company Reiterates Hold Rating on Clearside Biomedical (CLSD)
May 12, 2022 05:55AM Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target
May 10, 2022 06:23AM Heron Therapeutics (HRTX) PT Lowered to $14 at Needham & Company on Slower Zynrelef Launch and Financing Overhang
May 10, 2022 05:43AM CRISPR Therapeutics (CRSP) PT Lowered to $52 at Stifel Following Q1 Report, "Continue to be Positive on CTX001 but Skepticism Towards CAR-T Programs"
May 6, 2022 11:22AM Nektar Therapeutics (NKTR) PT Lowered to $4.60 at Stifel, "NKTR-358 Remains Biggest Potential Value Driver"
May 6, 2022 06:49AM Needham & Company Maintains Hold Rating on Theravance Biopharma (TBPH), Analyst Sees no Meaningful Catalysts in 2022, Awaits Pipeline Progression
May 6, 2022 06:47AM Vir Biotechnology (VIR) PT Lowered to $35 at Needham & Company on sotrovimab Uncertainty, Buy Rating Maintained
May 6, 2022 06:42AM "CF Sales Trajectory is Sufficiently Reflected in the Stock at Current Levels" - Needham & Company Maintains Vertex (VRTX) at Hold
May 6, 2022 06:22AM Sangamo BioSciences (SGMO) PT Lowered to $4.40 at Stifel
May 6, 2022 05:59AM Stifel Reiterates Buy Rating, $26 Price Target on Iovanace Biotherapeutics (IOVA)
May 6, 2022 05:58AM Mizuho Securities Reiterates Buy Rating on Arcutis Biotherapeutics (ARQT), "Like the Risk/Reward Setup" Heading Into Multiple Catalysts
May 6, 2022 05:56AM Needham & Company Reiterates Buy Rating, $14 Price Target on Aerie Pharma (AERI), "Reducing Cash Burn Remains a Focus"
May 6, 2022 05:55AM Needham & Company Reiterates Buy Rating, $75 Price Target on Rocket Pharmaceuticals (RCKT)
May 6, 2022 05:54AM Needham & Company Reiterates Buy Rating, $14 Price Target on NextCure Inc. (NXTC)
May 6, 2022 05:53AM Needham & Company Reiterates Buy Rating, $27 Price Target on Generation Bio (GBIO)
May 5, 2022 09:14AM uniQure BV (QURE) PT Slashed to $37 at Stifel on Q1 Results, but Analyst Reiterates Buy Rating Ahead of AMT-130 Readout
May 5, 2022 07:56AM Ionis Pharmaceuticals (IONS) PT Raised to $33 at Stifel on Q1 Results
May 5, 2022 06:49AM Needham & Company Reiterates Buy Rating, $70 Price Target on Apellis Pharmaceuticals (APLS)
May 5, 2022 06:46AM Needham & Company Reiterates Buy Rating, $150 Price Target on Sarepta Therapeutics (SRPT), "We Continue to View SRPT as the Industry Leader"
May 5, 2022 06:43AM Cytokinetics (CYTK) PT Raised to $60 at Needham & Company on Higher Price of mavacamten, Focus Remains on omecamtiv PDUFA
May 5, 2022 06:28AM Truist Securities Reiterates Buy Rating, $14 Price Target on Cyclerion Therapeutics (CYCN), Views "Nitrinergic System as Ripe for Therapeutic Intervention"
May 5, 2022 05:59AM Mirati Therapeutics (MRTX) PT Lowered to $115 at Stifel, Sees Near-Term Risk in 1L NSCLC Lumakras+pembro Data
May 4, 2022 09:09AM Dawson James Reiterates Buy Rating, $16 Price Target on CytoSorbents (CTSO)
May 4, 2022 08:11AM BMO Capital Maintains Underperform Rating on Neurocrine Bio (NBIX), "Outlook for Ingrezza Has Not Changed"
May 4, 2022 07:40AM BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN), Awaits Key Data from Oncology Programs
May 4, 2022 07:22AM Needham & Company Reiterates Buy Rating, $55 Price Target on Phathom Pharmaceuticals (PHAT) Following Voquezna Approval
May 4, 2022 06:30AM Truist Securities Reiterates Buy Rating, $60 Price Target on PTC Therapeutics (PTCT)
May 4, 2022 06:28AM William Blair Reiterates Outperform Rating on Brickell Biotech (BBI) on SB Sale, "Valuation Holds Strong Risk/Reward Profile"
May 4, 2022 06:26AM Stifel Reiterates Buy Rating, $16 Price Target on SeaSpine Holdings (SPNE) Following the Company's Q1 Report
May 4, 2022 06:25AM Mizuho Securities Reiterates Neutral Rating on Pfizer (PFE), Seeks More Clearance on Longer-Term Outlook
May 4, 2022 06:23AM Sage Therapeutics (SAGE) PT Lowered to $37 at Mizuho Securities, "Continue to Have Questions on zuranolone"
May 4, 2022 06:21AM Stifel Reiterates Buy Rating, $10 Price Target on Apollo Endosurgery (APEN)
May 4, 2022 06:19AM Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) Following Q1 Report, Sees "Likely Share Price Appreciation"
May 4, 2022 06:17AM "All Eyes on wAIHA Phase 3 Data Next Month" - H.C. Wainwright Reiterates Buy Rating, $11 Price Target on Rigel Pharmaceuticals (RIGL)
May 4, 2022 06:16AM H.C. Wainwright Reiterates Buy Rating, $45 Price Target on Pliant Therapeutics (PLRX)
May 3, 2022 06:11PM Mizuho Securities Reiterates Buy Rating, $57 Price Target on Arcutis Biotherapeutics (AQRT), Cites INCY's Opzelura's High Pace of Adoption
May 3, 2022 10:46AM Stifel Reiterates Buy Rating, $58 Price Target on Sage Therapeutics (SAGE)
May 3, 2022 10:21AM Dawson James Reiterates Buy Rating, $6 Price Target on Lineage Cell Therapeutics (LCTX)
May 3, 2022 10:11AM Truist Securities Reiterates Buy Rating on Verona Pharma (VRNA), Sees "High Probability of Success" of ensifentrine in Phase 3
May 3, 2022 09:51AM Stifel Reiterates Hold Rating on Biogen (BIIB), Views lecanemab Readout as "Risky"
May 3, 2022 07:56AM Mizuho Securities Reiterates Buy Rating, $95 Price Target on Incyte (INCY)
May 3, 2022 07:48AM BMO Capital Reiterates Market Perform Rating on Biogen (BIIB), "Encouraged with Potential New Leadership... Remain on Sidelines Given Risk Into Lecanemab Data"
May 3, 2022 07:42AM Truist Securities Reiterates Buy Rating, $320 Price Target on Biogen (BIIB) Following Q1 Report, "Focus Remains on Lecanemab Data 3Q22"
May 3, 2022 06:57AM Cantor Fitzgerald Reiterates Overweight Rating, $85 Price Target on Cutera (CUTR)
Apr 29, 2022 04:29PM Truist Securities Reiterates Buy Rating, $160 Price Target on Abbvie (ABBV)
View More Recent Stories View Older Stories